{
    "symbol": "LIFE",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-15 23:13:08",
    "content": " But it also has, I think, led a fire around the patients, the providers, the internal team here to say, let's really try to actually see if this drug could have even more steroid sparing effects, maybe a steroid replacement type of effect for certain patients. It's why I think the market opportunity is closer to $3 billion when you talk about what efzofitimod could do for patients, not only sarcoidosis, but in a number of interstitial lung disease."
}